ClinicalTrials.gg
Not yet recruitingNCT07666672Updated Oct 7, 2026

Digital Coach to Support Exposure Therapy Homework for Anxious Youth

An interventional study of BraveBot and Self-Guided Exposure Therapy Homework in Anxiety Disorders and OCD, sponsored by Massachusetts General Hospital. Not yet recruiting at 3 sites in United States. Open to participants aged 12 Years to 22 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
12 Years to 22 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Anxiety Disorders by Massachusetts General Hospital — 14 open to participants now, 20 under way, none of them phase 3. Anxiety Disorders · Massachusetts General Hospital.

Planned enrollment
40th of 64
50 · median 63
Started
2027
with 1 other
No phase
40 of 67
12 open now
Primary completion
2027-07
later than 11 of 19 live
Registered
65th of 67
by date

Among the 67 studies in Anxiety Disorders by Massachusetts General Hospital, this one is the 40th largest by planned enrollment of the 64 interventional ones that give a count, is one of 2 that started in 2027, is one of 40 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 65th registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

14 of the 67 studies in Anxiety Disorders by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 12 Years to 22 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Anxiety Disorders by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This study is testing a digital tool called BraveBot for young people who are receiving cognitive behavioral therapy (CBT) for anxiety, OCD, or related problems. BraveBot is a computer program, not a person. It talks with youth through their phone or computer while they do "face-your-fears"-style exposure therapy homework that their therapist has assigned. Sometimes an exposure is done with BraveBot's real-time coaching, and sometimes on their own; after each exposure, youth answer a few short questions about how it went.

Rather than dividing participants into separate groups, the study randomizes each individual exposure homework assignment. Every time a young person opens an eligible exposure, the system makes a 1:1 random assignment deciding whether that exposure is completed with BraveBot's support or independently (self-guided).

The main goal is to learn whether using BraveBot helps youth understand their exposure assignments better, put in more effort, stick with exposures when they are hard, feel more capable, and find exposures more helpful in "fighting back" against anxiety. The study also examines whether BraveBot increases the likelihood that assigned exposures are completed, and explores effects on anxiety symptoms and how safe, easy to use, and useful BraveBot feels for youth, their therapists, and parents.

BraveBot does not replace the therapist, diagnose, or design exposures; it only supports the homework the clinician has assigned, and is used under clinician oversight. A built-in safety system can detect possible risk-related language, pause the session, show crisis resources (such as 988), and notify the treating clinician. The study is conducted within routine outpatient psychology clinics at Mass General Brigham. Up to 40 youth ages 12-22 will take part.

Read the detailed description

Design. Open-label, within-participant, exposure-instance-level randomized trial embedded in routine outpatient exposure-based CBT at Mass General Brigham clinics. The unit of randomization is the individual clinician-assigned, "BraveBot-eligible" exposure homework instance. Each time a youth opens the link for a BraveBot-eligible exposure delivered via SMS reminder, the backend system immediately randomizes that single instance 1:1 to BraveBot-assisted vs self-guided completion.

Intervention. BraveBot is a scope-limited, clinician-supervised, large language model (GPT)-powered audio-to-audio conversational assistant (provided by TheraLoop AI, Inc.) that supports completion of clinician-assigned exposure homework. For BraveBot-assisted instances it clarifies the assignment and rationale, collects Subjective Units of Distress (SUDS) ratings and expectations, encourages persistence when anxiety rises, prompts about safety behaviors and "white-knuckling" at mid-exposure check-ins, and guides brief end-of-exposure reflection. It does not diagnose, generate exposure hierarchies, or make treatment decisions. For self-guided instances, the youth completes the same assigned exposure independently and then completes the same post-exposure survey.

Aims.

Aim 1 (primary): whether BraveBot improves exposure-homework QUALITY, assessed by five youth-reported 0-100 ratings per completed instance (Effort, Perceived Capability, Understanding, Ability to Continue, Perceived Helpfulness).

Aim 2 (secondary): whether BraveBot increases exposure-homework ADHERENCE (probability that a randomized instance is completed).

Aims 3-5 (exploratory): preliminary effects on clinical outcomes (RCADS anxiety, CALIS-C life interference, IUSC intolerance of uncertainty) and associations with exposure-related processes; acceptability/usability/burden among youth, clinicians, and parents; and the performance and burden of BraveBot's automated risk-detection and clinician-notification (safety) workflow.

Participants and schedule. Up to 40 youth ages 12-22 with a clinical or subclinical anxiety or related disorder for which exposure-based CBT is indicated. BraveBot access remains active for up to 45 homework-reminder days (about six weeks), with a 12-week backstop (i.e., 84 calendar days). Standardized self-report measures are collected at baseline (pre-BraveBot), at the end of the active BraveBot period, and at a \~3-week follow-up. A separate population of up to 10 clinicians may voluntarily enroll to use the BraveBot system with their patients and complete surveys about their experience.

Analysis. Primary outcomes are analyzed with linear mixed-effects models (fixed effect of condition; random intercepts for youth, and clinician/site as needed), with Benjamini-Hochberg false-discovery-rate correction across the five co-primary outcomes. Adherence is analyzed with a binomial-logit generalized linear mixed-effects model.

03

Conditions studied

  • Anxiety Disorders
  • OCD

Browse trials for

Keywords

  • anxiety
  • exposure therapy
  • pediatric
  • large language model
  • conversational AI
  • randomized controlled trial
04

Who can participate

Ages eligible
12 Years to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a clinical or subclinical anxiety or related disorder (e.g., panic disorder, social anxiety disorder, obsessive-compulsive disorder) for which exposure-based CBT is indicated.
  2. Between the ages of 12 and 22 years at the time of enrollment.
  3. Is either (a) currently receiving exposure-based CBT (or CBT in which exposure-based content is expected to be a core component) at a participating MGB outpatient program, or (b) on the waitlist for a participating program and expected to initiate exposure-based CBT in the near future.
  4. Sufficient ability to communicate in English (study materials, measures, and the BraveBot interface are currently English-only). For minors, at least one parent/guardian must be sufficiently proficient in English to understand the consent information.
  5. The youth and/or caregiver has access to a device that can receive SMS text reminders and open secure web links to complete exposure homework and brief post-exposure surveys.

Exclusion criteria

EXCLUSION CRITERIA (present at enrollment):

  1. Symptoms of suicidal or homicidal ideation, psychosis, or a non-anxiety-related primary mental health concern (i.e., where treatment for a disorder other than anxiety is indicated prior to exposure treatment, or independent exposure homework is not clinically appropriate as determined by the treating clinician). Examples include: current substance use or dependence requiring specialized or higher-level care that must be addressed before or instead of anxiety-focused exposure-based CBT; and current eating disorder severe enough to require intensive/specialized treatment such that exposure-based CBT for anxiety/OCD is not the appropriate primary focus.
  2. Youth is unable to complete homework independently.
  3. Any other condition or circumstance for which treatment for another primary psychiatric condition is clearly indicated prior to anxiety-focused exposure-based CBT, or for which out-of-session exposure homework is considered unsafe or inappropriate.

The investigators will also recruit up to 10 clinicians at participating programs who may use the BraveBot system with their patients (who have enrolled in the study independently) and complete brief baseline and end-of-study surveys.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    BraveBot-Assisted Exposure

    Exposure instances randomized to this condition are completed with BraveBot, an LLM-powered audio-to-audio conversational assistant that provides real-time, structured coaching: clarifying the assigned exposure and its rationale, collecting SUDS ratings, encouraging persistence, prompting about safety behaviors and 'white-knuckling' at mid-exposure check-ins, and guiding brief post-exposure reflection.

    Behavioral: BraveBot

  • Active comparator
    Self-Guided Exposure

    Exposure instances randomized to this condition are completed independently by the youth (standard self-guided homework), without BraveBot coaching; the youth then completes the same brief post-exposure survey.

    Behavioral: Self-Guided Exposure Therapy Homework

Interventions

  • BehavioralBraveBot

    Scope-limited, clinician-supervised, GPT-powered audio-to-audio conversational assistant delivered via a secure web link in SMS reminders. Supports clinician-assigned exposure homework by clarifying instructions and rationale, collecting SUDS, encouraging persistence, prompting about safety behaviors and white-knuckling, and guiding post-exposure reflection. Includes an automated risk-detection workflow that pauses the session, shows crisis resources, and notifies the treating clinician.

    Also known as: BraveBot by TheraLoop AI, Inc.

  • BehavioralSelf-Guided Exposure Therapy Homework

    The youth completes the same clinician-assigned exposure independently, without BraveBot coaching (standard between-session homework).

06

What researchers measure

Primary outcomes

  1. Exposure Quality -- Effort (0-100)

    Youth-reported effort put into the exposure, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater effort (better).

    Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).

  2. Exposure Quality -- Perceived Capability (0-100)

    Youth-reported sense of being capable to approach or handle anxiety-provoking situations, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater perceived capability (better).

    Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).

  3. Exposure Quality -- Understanding (0-100)

    Youth-reported understanding of what to do and why during the exposure, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater understanding (better).

    Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).

  4. Exposure Quality -- Ability to Continue When Distressed (0-100)

    Youth-reported ability to stay with the exposure when it was difficult or distressing, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater ability to continue (better).

    Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).

  5. Exposure Quality -- Perceived Helpfulness (0-100)

    Youth-reported helpfulness of the exposure in reducing anxiety, rated on a 0-100 slider after each completed randomized exposure instance. Minimum 0, maximum 100; higher scores indicate greater perceived helpfulness (better).

    Time frame: Immediately after each completed, randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).

Secondary outcomes

  1. Exposure-homework Adherence

    Proportion of randomized exposure instances classified as Complete (vs. Incomplete), compared between BraveBot-assisted and self-guided conditions. Completion is determined automatically from condition-specific workflow flags. Reported as a proportion (0-1); a higher completion proportion for BraveBot-assisted vs. self-guided is better.

    Time frame: For each randomized exposure instance during the active BraveBot period (up to 45 homework-reminder days, or the 12-week backstop).

Other outcomes

  1. Revised Children's Anxiety and Depression Scale (RCADS) - Total Anxiety (youth-report)

    Anxiety symptom measure; each item scored 0 (Never) to 3 (Always). The Total Anxiety score is the sum of the five anxiety subscales (separation anxiety, social phobia, generalized anxiety, panic, obsessive-compulsive). Total Anxiety score range 0-111; higher scores indicate greater anxiety symptoms (worse).

    Time frame: Baseline, end of active BraveBot period (average of ~6 weeks, up to max of 12 weeks), and follow-up (3 weeks following end of active BraveBot period).

  2. Child Anxiety Life Interference Scale (CALIS) (youth-report)

    Self-report measure of anxiety-related interference in the child's daily life. Each of the 8 items are rated on a 0-4 scale. Total score range 0-32; higher scores indicate greater anxiety-related life interference (worse).

    Time frame: Baseline, end of active BraveBot period (average of ~6 weeks, up to max of 12 weeks), and follow-up (3 weeks following end of active BraveBot period).

  3. Intolerance of Uncertainty Scale-Child (IUSC) (youth-report)

    Self-report measure of intolerance of uncertainty; items rated 1-5. Total score range 27-135; higher scores indicate greater intolerance of uncertainty (worse).

    Time frame: Baseline, end of active BraveBot period (average of ~6 weeks, up to max of 12 weeks), and follow-up (3 weeks following end of active BraveBot period).

  4. Memory for Treatment Content (youth-report)

    Vignette-based, multiple-choice assessment of memory for exposure-CBT principles, scored as proportion correct (0-100%); higher scores indicate better memory for treatment content (better).

    Time frame: End of active BraveBot period (average of ~6 weeks, max of 12 weeks) and follow-up (3 weeks later).

  5. Developmentally Adapted or Original Version of the System Usability Scale (SUS) (youth- and clinician-report)

    Standardized usability measure of the BraveBot system (developmentally adapted for youth; standard version for clinicians). Score range 0-100; higher scores indicate better perceived usability (better).

    Time frame: End of active BraveBot period for youth (i.e., ~6 weeks on average, max of 12 weeks); end of study for clinicians (anticipated to be one year after recruitment begins).

  6. Global Post-BraveBot Peference/Acceptability ratings (youth-report)

    Youth-reported 0-100 slider ratings comparing BraveBot-assisted vs. self-guided exposure (e.g., effort, persistence, understanding, helpfulness, enjoyment, preference, future use, safety, willingness to recommend). Each item: minimum 0, maximum 100; higher scores indicate a more favorable rating of BraveBot.

    Time frame: End of active BraveBot period (i.e., ~6 weeks on average, max of 12 weeks).

  7. Clinician Attitudes Toward AI

    Clinician-reported AI-attitudes scale at orientation (items rated on 1-5 scale; total scores range from 7 to 35); higher scores indicate more favorable attitudes.

    Time frame: At baseline (orientation) and end of study (anticipated to be one year after recruitment begins)

  8. Clinician Questionnaire - Global Feedback on BraveBot

    0-100 global ratings of BraveBot's effects on exposure homework, workflow fit, acceptability, and clinical alignment, plus open-text feedback; higher scores indicate more favorable ratings.

    Time frame: End of study (anticipated to be one year after recruitment begins).

  9. Novel Parent/Caregiver Perceptions of BraveBot Questionnaire

    For parents/caregivers of youth participants under 18 years of age, 0-100 sliders comparing BraveBot-supported vs self-guided exposure homework (e.g., child willingness/engagement, persistence during distress, independence from parent, parent-child conflict/stress, structure/guidance, comfort/appropriateness, future preference, and concerns about AI).

    Time frame: At the end of the youth participant's active BraveBot period (i.e., ~6 weeks on average, max of 12 weeks).

  10. Number of Automated Safety Alerts

    Count of automated safety alerts generated by BraveBot's risk-detection workflow during BraveBot-assisted exposures. Reported as a count.

    Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).

  11. Clinician Response Time to Safety Alerts

    Time from generation of an automated safety alert to documented clinician review, in hours. Reported as hours.

    Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).

  12. Proportion of Safety Alerts Classified as True Positive vs. False Positive

    Among automated safety alerts reviewed by clinicians, the proportion classified as genuine concern (true positive) vs. false positive. Reported as a percentage.

    Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).

  13. Number of Clinician-Initiated Manual Safety Flags

    Count of safety concerns flagged by clinicians that were not captured by the automated workflow (potential false negatives). Reported as a count.

    Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).

  14. Number of Youth-Reported "I Felt Unsafe" Responses

    Count of post-exposure surveys on which a youth endorsed the "I felt unsafe" item. Reported as a count.

    Time frame: Throughout the active BraveBot period (i.e., average of 6 weeks; up to 12 weeks at most).

07

Study locations

3 sites
08

References and documents

Publications

  • Zieve, G. G., Dong, L., & Harvey, A. G. (2019). Patient Memory for Psychological Treatment Contents: Assessment, Intervention, and Future Directions for a Novel Transdiagnostic Mechanism of Change. Behaviour Change, 36(1), 1-11. https://doi.org/10.1017/bec.2019.1
  • Lyneham HJ, Sburlati ES, Abbott MJ, Rapee RM, Hudson JL, Tolin DF, Carlson SE. Psychometric properties of the Child Anxiety Life Interference Scale (CALIS). J Anxiety Disord. 2013 Oct;27(7):711-9. doi: 10.1016/j.janxdis.2013.09.008. Epub 2013 Sep 26. PubMed 24135256 ↗
  • Harvey AG, Dong L, Lee JY, Gumport NB, Hollon SD, Rabe-Hesketh S, Hein K, Haman K, McNamara ME, Weaver C, Martinez A, Notsu H, Zieve G, Armstrong CC. Can integrating the Memory Support Intervention into cognitive therapy improve depression outcome? Study protocol for a randomized controlled trial. Trials. 2017 Nov 14;18(1):539. doi: 10.1186/s13063-017-2276-x. PubMed 29137655 ↗
  • Dong L, Lee JY, Harvey AG. Memory support strategies and bundles: A pathway to improving cognitive therapy for depression? J Consult Clin Psychol. 2017 Mar;85(3):187-199. doi: 10.1037/ccp0000167. PubMed 28221056 ↗
  • Comer JS, Roy AK, Furr JM, Gotimer K, Beidas RS, Dugas MJ, Kendall PC. The intolerance of uncertainty scale for children: a psychometric evaluation. Psychol Assess. 2009 Sep;21(3):402-11. doi: 10.1037/a0016719. PubMed 19719351 ↗
  • Chorpita BF, Yim L, Moffitt C, Umemoto LA, Francis SE. Assessment of symptoms of DSM-IV anxiety and depression in children: a revised child anxiety and depression scale. Behav Res Ther. 2000 Aug;38(8):835-55. doi: 10.1016/s0005-7967(99)00130-8. PubMed 10937431 ↗
  • Brooke, J. (1995). SUS: A quick and dirty usability scale. Usability Eval. Ind., 189.
  • Bekes V, Aafjes-van Doorn K. Who Wants to Have an AI Therapist? Acceptance of Using Artificial Intelligence for Mental Health Interventions Among Clinicians, Patients and the General Community. Clin Psychol Psychother. 2026 Jan-Feb;33(1):e70220. doi: 10.1002/cpp.70220. PubMed 41578705 ↗

Individual participant data

Plan to share: No — No routine sharing of individual participant data is planned at this time. De-identified, coded analytic datasets may be shared with named collaborators (Harvard University and TheraLoop AI, Inc.) under appropriate agreements and IRB approval. No deposit of individual-level data in public repositories is planned.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Jul 2027, 5 months later.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 5 months is below that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Feb 2027, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 24, 2026
StartEst.
Feb 1, 2027was Jul 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 15, 2026→Feb 1, 2027
Oct 7, 2026
Primary completion
Jul 15, 2027→Jul 31, 2027
Oct 7, 2026
Study completion
Jul 15, 2027→Jul 31, 2027
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Start date Jul 15, 2026→Feb 1, 2027
    Primary completion Jul 15, 2027→Jul 31, 2027
    Study completion Jul 15, 2027→Jul 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07666672
Collaborators
Harvard University, Mclean Hospital, TheraLoop AI, Inc.
Responsible party
Madelaine R. Abel, PhD (Assistant Professor, Massachusetts General Hospital) — Principal investigator
First posted
Jun 24, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Joshua S Steinberg, MA
Contact
jssteinberg@mgb.org
6179453115
Madelaine R Abel, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion